Talphera, Inc., was originally registered in Delaware as SuRX, Inc., on July 13, 2005. The company subsequently changed its name to AcelRx Pharmaceuticals, and the company changed its name from "AcelRx Pharmaceuticals, Inc." to "Talphera, Inc." on January 10, 2024. The Company is a specialty pharmaceutical company focused on the development and commercialization of therapies for medical monitoring settings, with current R&D efforts focused on the regional anticoagulant Niyad for the dialysis circuit and the possible development of LTX-608 for other indications.
